Status: Not yet recruiting
Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Establishing real-world data of Chinese patients with CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) treated with Puzolcabtagene Autoleucel Injection to evaluate its effectiveness.
Participants needed: 200
Trial details
Biological sex: AllType: ObservationalSponsor: Chongqing Precision Biotech Co., LtdUpdated: Jun 10, 2026Duration: 2 Years
Eligibility criteria
Patients with r/r B-ALL who receive treatment with Pucicelant Injection at a res... [+2]
Patients who test positive for hepatitis C virus (HCV), human immunodeficiency v...